Silo Pharma (SILO) entered a nonbinding letter of intent with Hoth Therapeutics (HOTH) to form a 50-50 joint venture aimed at developing and commercialize treatments for obesity and metabolic diseases.
The initiative will build on Hoth's technology, which is exclusively licensed from the US Department of Veterans Affairs and co-developed with Emory University, Silo Pharma said Wednesday in a statement.
Silo Pharma shares eased 0.1% in recent trading Wednesday, and Hoth Therapeutics fell 4.1%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.